Hospital Universitario Marqués de Valdecilla -ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2024

  1. 18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study

    Expert Review of Hematology, Vol. 17, Núm. 1-3, pp. 95-100

  2. Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study

    Cancers, Vol. 16, Núm. 7

  3. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  4. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

  5. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study

    British Journal of Haematology, Vol. 203, Núm. 2, pp. 182-193

2022

  1. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

  2. Humoral/Cellular Immune Discordance in Stem Cell Donors: Impact on Cytomegalovirus-Specific Immune Reconstitution after Related Hematopoietic Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 703.e1-703.e8

2021

  1. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

2019

  1. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

    European Journal of Haematology, Vol. 102, Núm. 6, pp. 465-471

  2. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1825-1831

2017

  1. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2014

  1. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: A multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study

    British Journal of Haematology, Vol. 164, Núm. 5, pp. 668-674

2006

  1. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia

    Bone Marrow Transplantation, Vol. 37, Núm. 1, pp. 33-40

2004

  1. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

    Bone Marrow Transplantation, Vol. 34, Núm. 1, pp. 13-20

2000

  1. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: The Spanish experience

    Haematologica, Vol. 85, Núm. 5, pp. 530-538